Niagen Bioscience Inc (NAGE) FinancialsNAGEFinancialNiagen Bioscience Inc

Niagen Bioscience Inc (NAGE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumer Products Segments, accounting for 81.1% of total sales, equivalent to $24.16M. Other significant revenue streams include Ingredients Segments and Corporate and other. Understanding this composition is critical for investors evaluating how NAGE navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Niagen Bioscience Inc maintains a gross margin of 64.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 2.35%, while the net margin is 3.23%. These profitability ratios, combined with a Return on Equity (ROE) of 21.80%, provide a clear picture of how effectively NAGE converts its operational activities into shareholder value.

In the context of the broader market, NAGE competes directly with industry leaders such as USNA and NATR. With a market capitalization of $260.32M, it holds a significant position in the sector. When comparing efficiency, NAGE's gross margin of 64.84% stands against USNA's 78.35% and NATR's 73.66%. Such benchmarking helps identify whether Niagen Bioscience Inc is trading at a premium or discount relative to its financial performance.

Niagen has shown solid financial performance with total revenue for Q2 2026 at $29.8 million, and a gross margin of 64.84%. Despite challenges, it reported a net income of $963,000 in Q2 2026, reflecting resilience in its operations.